SKC podcast

#14 Update from Brussels – between EU-HTA and Pharma Package

Mon, 2023 / 07 / 31
Dr. Alexander Natz is partner of the life sciences industry specialized law firm NOVACOS in Düsseldorf and secretary general of the European Confederation of Pharmaceutical Entrepreneurs, EUCOPE.

In the Profcast "Rare diseases and their therapies" he discusses the latest developments of the European health technology assessments (EU-HTA), the influence of the German authorities and the upcoming innovations of the "EU Pharmaceutical Package" for manufacturers of orphan drugs with his host Prof. Dr. Matthias P. Schönermark.

You can find Profcast #14 Update from Brussels – between EU-HTA and Pharma Package on Spotify and Apple Podcast (in German language only). Tune in!

About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.

About the author

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Orphan Drugs


Orphan drugs and the specific market access challenges are at the core of our expertise.

Whitepaper


Successful market access for gene therapies - Strategic challenges and possible solutions
to the top
powered by webEdition CMS